3 results
The primary objective of the study is to determine whether the optimal atrioventricular delay and interventricular delay in cardiac resynchronization therapy are a function of exercise. Secondary objectives are the development of an automatic…
The VOLT AF First-in-Human (FIH) study will collect feasibility data to show that the Volt PFA System functions as intended in a clinical setting and to demonstrate acute safety and effectiveness for the treatment of symptomatic, recurrent…
The objectives of this are to establish the safety, tolerability, and efficacy of VRDN-001, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of VRDN-001 in HV and TED patients over a dose range of 3.0 to 20.0 mg/kg.